How quickly do semaglutides work — and what does the evidence say?

What happens in the first four weeks, and why the scales can mislead you

The pharmacology of semaglutide moves faster than the scales do. GLP-1 receptor agonism kicks in after the first injection: gastric emptying slows, satiety signals rise, and most people notice reduced hunger within the first week. The NHS medicines information for semaglutide notes that gastrointestinal effects (nausea, loose stools, a full feeling after small portions) are most common in these early weeks, partly because the drug is doing exactly what it should.

The starting dose (0.25mg for Wegovy) is a tolerability dose. Its job is to help your body adjust, not to deliver the full therapeutic effect. So if the first month brings modest weight change, that is expected and by design. Some people do see early movement of 1–2kg; others see very little until the dose steps up. Neither outcome tells you how well you will ultimately respond.

What you can do right now: weigh yourself once a week, same time, same clothing, and note the trend rather than individual readings. Day-to-day fluctuations of 1–2kg are normal fluid shifts. A four-week average is a far more useful signal than any single morning number.

Weeks four to sixteen, the escalation window and when results begin to compound

Each dose increase brings another step-change in appetite suppression. For Wegovy, the schedule moves from 0.25mg through 0.5mg, 1.0mg, 1.7mg, and then 2.4mg, with roughly four weeks at each level. The STEP 1 trial data show that average weekly weight loss accelerates through this escalation phase. Most participants were not at their maximum dose until around week 16, which is why comparing your week-six progress against a friend's week-twenty results is rarely informative.

Side effects also tend to ease as each new dose becomes familiar. The nausea that some people experience after stepping up typically settles within one to two weeks. Eating smaller meals, staying well hydrated, and avoiding very fatty foods in the first days after an increase all help. There is more practical detail on what to expect as Wegovy takes effect if you want a closer look at the dose-by-dose picture.

It is worth noting (and the STEP 1 results make this explicit) that the 15% average weight reduction at 68 weeks is an average across thousands of adults. Some responded more, some less. The maintenance dose is where most of the long-term benefit accumulates.

Six months and beyond, where the clinical trial endpoints sit

The STEP 1 primary endpoint was at 68 weeks. That figure (roughly 15% average body weight reduction versus 2.4% for placebo) represents sustained, consistent treatment over more than a year. Expecting equivalent results in twelve weeks sets an unfair benchmark. The weight-loss curve in trial data is steepest between months three and nine, then gradually flattens as the body reaches a new equilibrium at the maintenance dose.

For those weighing up options or costs, understanding this timeline matters practically. You can explore the cost of Wegovy treatment in the UK in context once you know what realistic duration of treatment looks like. NICE's recommendation under TA875 for NHS use notes that treatment should be reviewed if less than 5% weight loss is achieved after six months on the maintenance dose, a useful benchmark for private patients too, though the decision rests with your prescriber.

Questions about the precise timeline for your situation are best explored at consultation, where a prescriber can look at your health history and the dose you are likely to reach. More detail on the speed of response is covered in our guide to how quickly semaglutide kicks in.

Factors that influence how quickly results arrive

Trial averages describe populations, not individuals. Several things genuinely shift how fast someone responds. Starting BMI matters: people with a higher starting weight often see larger absolute losses early, though percentage loss may be similar. Metabolic health, insulin sensitivity, and whether type 2 diabetes is present all affect the drug's glucose-related mechanisms. And adherence to lifestyle changes alongside treatment (calorie intake, protein adequacy, physical activity) consistently predicts where on the response curve someone lands.

Dose tolerability shapes the timeline too. Someone who moves through the escalation schedule without significant side effects reaches the therapeutic maintenance dose faster than someone who needs a slower titration. That is not a failure; it is a clinical decision. Our prescribers review how long Wegovy typically takes to work at every clinical check-in, adjusting expectations as well as doses where needed.

Finally: the oral Wegovy tablet (approved in the UK in June 2026) follows a different escalation schedule and shows slightly different trial results from the injection. The Wegovy overview page covers both formats. If you are exploring your options, our clinical team (including our clinical lead) can help identify what is most likely to suit your situation.

Semaglutide works. The evidence on that is clear. The more precise question is always how quickly for you, and if you want a fuller picture before your consultation, our guide to how quickly Wegovy will work walks through what the evidence says at each stage. Speak to our prescribers through a free consultation to get an honest, personalised view.